# Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

> **NCT05254990** · PHASE3 · TERMINATED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 414 (actual)

## Conditions studied

- Infectious Pneumonia
- Severe COVID-19

## Interventions

- **DRUG:** Reparixin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05254990
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-27
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-09-27
- **Target enrollment:** 414 (ACTUAL)
- **Why stopped:** The study was stopped due to futility as per protocol
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254990, "Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05254990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*